

**Department of Defense  
Congressionally Directed Medical Research Programs (CDMRP)  
Peer Reviewed Medical Research Program (PRMRP)  
Funding Opportunities for Fiscal Year 2022 (FY22)**

The FY22 PRMRP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website.

[Funding Opportunities-FY22 PRMRP, Congressionally Directed Medical Research Programs \(CDMRP\), US DoD \(army.mil\)](#)

**Clinical Trial Award – Preproposal due May 6, 2022**

Assistant Professor level or above (or equivalent)

- Preproposal submission is required; application submission is by invitation only.
- Supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the topic area(s) of interest.
- Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.
- Two options will be offered:
  - o Planning Phase with Clinical Trial Option: Provides support to prepare and submit an Investigational New Drug/ Investigational Device Exemption (IND/ IDE) application to the U.S. Food and Drug Administration (FDA) and requires FDA/regulatory approval or exemption to proceed before the clinical trial may be funded.
  - o Clinical Trial Only Option: Provides support for the clinical trial. IND or IDE applications to the FDA, if needed, must be approved by the FDA and included in the application submission.

Clinical Trial:

- A funding limit is not defined; requested funding must be appropriate for the scope of work proposed.
- The maximum period of performance for the clinical trial is 4 years. Planning Phase with Clinical Trial Option:
  - The maximum allowable funding for the Planning Phase period of performance is \$500,000 for direct costs.
  - Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.
- The maximum period of performance for the clinical trial is 4 years.

**Discovery Award – Letter of Intent due April 22, 2022**

Postdoctoral fellow or clinical fellow (or equivalent and above)

Supports the exploration of a highly innovative new concept or untested theory.

- Not intended to support the logical progression of an already established line of questioning.
- Clinical trials will not be funded.

**Focused Program Award – Preproposal due May 6, 2022**

Full Professor level or above (or equivalent)

- Preproposal submission is required; application submission is by invitation only.

- Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal/question.
- Projects should work together to answer critical questions, resolve differing hypotheses, and translate laboratory findings to clinical applications.
- Projects may range from exploratory/ hypothesis-developing studies through small[1]scale clinical trials that together will address the overarching goal/question.
- Research team of highly qualified, multidisciplinary project leaders should be led by an investigator with demonstrated success in directing large, focused projects
  - The maximum allowable funding for the entire period of performance is \$7.2 million for direct costs.
  - Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.
  - The maximum period of performance is 4 years.

### **Investigator-Initiated Research Award – Letter of Intent due April 29, 2022**

Assistant Professor level or above (or equivalent)

Supports research that will make an original and important contribution to the field of research or patient care in the Topic Area(s) of interest.

- Partnering Principal Investigator Option available.
- Clinical trials will not be funded.

The maximum allowable funding for the entire period of performance is \$1.6 million for direct costs for single investigators and \$2.0 million for partnering investigators.

- Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.
- The maximum period of performance is 4 years.

### **Technology/Therapeutic Development Award – Letter of Intent due April 29, 2022**

Assistant Professor level or above (or equivalent)

- Supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, and/or quality of life.
- Supports product-oriented projects (e.g., device, drug, clinical guidelines). The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.

• Two funding levels are available depending on the maturity of the product. The following are general descriptions, although not all[1]inclusive, of the scope of research projects that would be appropriate to propose under each funding level:

o Funding Level 1: Supports research that is supported by significant preliminary data but has not advanced to the level of clinical translation.

o Funding Level 2: Supports research that is in the final states of preclinical development with potential for near-term clinical development. Applications must provide relevant data that support the rationale for the proposed study. Funding Level 2 recipients must submit or obtain an IND/IDE application to the FDA, or must transition the product to clinical practice, within the period of performance.

- Clinical trials will not be funded.

Funding Level 1:

- The maximum allowable funding for the entire period of performance is \$2 million for direct costs.
- Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.
- The maximum period of performance is 4 years. Funding Level 2:
- The maximum allowable funding for the entire period of performance is \$4 million for direct costs.
- Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.
- The maximum period of performance is 4 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at <https://eBRAP.org> prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

For email notification when announcements are released, subscribe to program-specific news and updates under "Email Subscriptions" on the eBRAP homepage at <https://eBRAP.org>. For more information about the PCARP or other CDMRP-administered programs, please visit the [CDMRP website \(https://cdmrp.army.mil\)](https://cdmrp.army.mil).

**Point of Contact:**  
CDMRP Help Desk  
301-682-5507  
[help@eBrap.org](mailto:help@eBrap.org)